Related Experiment Video
Updated: Aug 12, 2025
06:57
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
9.1K
IBD disease-modifying therapies: insights from emerging therapeutics
Niranjan G Kotla1, Yury Rochev1
1CÚRAM, Science Foundation Ireland (SFI) Research Centre for Medical Devices, University of Galway, Galway, Ireland.
Trends in Molecular Medicine
|January 31, 2023
Summary
Inflammatory bowel disease (IBD) involves gut barrier dysfunction. New therapies are needed to repair the gut lining and restore microbial balance, moving beyond symptom management for effective IBD treatment.
Area of Science:
- Gastroenterology
- Immunology
- Biomaterials Science
Background:
- Inflammatory bowel disease (IBD) pathogenesis involves gut mucosal inflammation, epithelial damage, and dysbiosis, leading to a compromised gut mucosal barrier.
- Current IBD treatments primarily manage symptoms but do not effectively address mucosal repair, barrier homeostasis, or intestinal dysbiosis.
- Existing strategies to enhance gut barrier function are in early development and have limited success.
Purpose of the Study:
- To review conventional therapies for IBD.
- To explore the role of gut barrier-protecting agents in IBD management.
- To discuss biomaterial strategies for combination therapies to improve IBD treatment.
Main Methods:
- Literature review of conventional IBD therapies.
- Analysis of research on gut barrier-protecting agents.
- Evaluation of biomaterial applications in IBD therapeutic strategies.
Main Results:
- Conventional therapies offer symptomatic relief but fail to restore gut barrier integrity or microbial balance.
- Gut barrier-protecting agents show potential but require further investigation for efficacy in IBD.
- Biomaterial-based approaches offer novel avenues for combination therapies to enhance gut barrier function.
Conclusions:
- There is a critical need for therapeutic strategies that target mucosal epithelial repair and barrier homeostasis in IBD.
- Combination therapies integrating barrier-protecting agents and biomaterials may represent a promising future direction for IBD treatment.
- Further research is essential to develop and validate these novel approaches for IBD.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
230
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
230
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
205
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
205
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
181
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
181
01:29Drugs for Treatment of Ulcerative Colitis in IBD
212
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
212
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
385
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
385